Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,911,551

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Stock Market News For Feb 7, 2019

U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.

Sanofi's Myeloma Candidate Meets Goal in Phase III Study

Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.

Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.

Roche Submits sBLA to FDA for Label Expansion of Kadcyla

Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Lilly (LLY) Hits 52-Week High, Can the Run Continue?

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.

Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study

Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.

Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV

J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.

Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds

Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA

Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.